Premium Nahrungsergänzungsmittel | artgerecht

Romosozumab – Mechanism, Dosage & Side Effects

Romosozumab is a monoclonal antibody used to treat osteoporosis. It works by stimulating bone formation and reducing bone resorption simultaneously.

Regular tips about health Regular tips about health

Things worth knowing about "Romosozumab"

Romosozumab is a monoclonal antibody used to treat osteoporosis. It works by stimulating bone formation and reducing bone resorption simultaneously.

What is Romosozumab?

Romosozumab is a monoclonal antibody used in the treatment of osteoporosis. It is a biologic medication that specifically targets the bone remodeling process. Marketed under the brand name Evenity, romosozumab is approved in numerous countries for postmenopausal women at high risk of fracture. What makes romosozumab unique is its dual mechanism of action: it simultaneously increases bone formation and decreases bone resorption.

Indication

Romosozumab is approved for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture. Typical indications include:

Patients who have already experienced an osteoporotic fracture
Patients with very low bone mineral density (BMD)
Cases where previous osteoporosis therapies were insufficient or not tolerated

Mechanism of Action

Romosozumab works by binding specifically to sclerostin, a protein naturally produced by osteocytes (bone cells) that inhibits bone formation. Sclerostin suppresses the Wnt signaling pathway, which is essential for activating bone-forming cells called osteoblasts.

By neutralizing sclerostin, romosozumab acts on two levels at once:

Bone formation (anabolic effect): Osteoblast activity is enhanced, leading to the creation of new bone tissue.
Inhibition of bone resorption (antiresorptive effect): The activity of bone-resorbing cells (osteoclasts) is simultaneously reduced.

This dual approach sets romosozumab apart from other osteoporosis medications such as bisphosphonates (purely antiresorptive) or teriparatide (purely anabolic).

Dosage and Administration

Romosozumab is administered as a subcutaneous injection (under the skin). The recommended dose is 210 mg once monthly, given as two consecutive injections of 105 mg each at separate sites. The treatment duration is limited to 12 months. After completing romosozumab therapy, a follow-up antiresorptive treatment (e.g., bisphosphonates) is generally recommended to maintain the bone gains achieved.

Side Effects

Romosozumab is generally well tolerated, but side effects can occur:

Common: Injection site reactions (redness, pain, swelling), joint pain (arthralgia), headache
Occasional: Muscle pain, peripheral edema
Rare but important: Increased risk of serious cardiovascular events (myocardial infarction, stroke) – particularly in patients with pre-existing cardiovascular disease
Very rare: Osteonecrosis of the jaw, atypical femoral fractures

Contraindications and Warnings

Romosozumab must not be used in:

Patients with a history of myocardial infarction or stroke (within the past year)
Known hypersensitivity to the active substance or any excipients
Hypocalcemia (low blood calcium levels) – this must be corrected before starting therapy

Prior to initiating treatment, adequate calcium and vitamin D supplementation should be ensured to prevent hypocalcemia.

Clinical Studies and Efficacy

The efficacy of romosozumab has been demonstrated in large clinical trials:

FRAME Study: Demonstrated a significant reduction in vertebral and non-vertebral fractures compared to placebo after 12 months.
ARCH Study: Compared romosozumab followed by alendronate versus alendronate alone. Romosozumab showed a significantly greater reduction in fracture risk.

These studies confirmed that romosozumab substantially increases bone mineral density and markedly reduces the risk of vertebral and hip fractures.

References

Cosman F et al. - Romosozumab Treatment in Postmenopausal Women with Osteoporosis. New England Journal of Medicine, 2016.
European Medicines Agency (EMA) - Evenity (Romosozumab): European Public Assessment Report. EMA, 2019. Available at: www.ema.europa.eu
Saag KG et al. - Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. New England Journal of Medicine, 2017.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.